Follow The Filings

ACAD Acadia Pharmaceuticals Inc.

Health Care, filed as ACADIA PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 10.0%
  • $72M
  • 1 exit 1 small

In 2026 Q2 David Witzke sold out of Acadia Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 10.0% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors Reduce 10.0%

Who owns ACAD

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 10.0% Small trim −0.3% 2,864,096 $72M History
David Witzke, Avidity Partners Management exited 2026 Q2 Last 2026 Q1 0.07% Exit −0.07% 12,967 $291K History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ACAD's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ACAD insider trades
  • None no insider bought on the open market
  • $785K sold by 2 insiders outside a trading plan
  • $885K sold by 2 insiders under 10b5-1 plans
  1. Mark C. Schneyer CFO
    Planned sale
    $587K 20,141 shares at $29.16 23% of stake
    Traded Aug 5–6 Filed Aug 7
    ↗
  2. James Kihara Principal Accounting Officer
    Planned sale
    $298K 11,421 shares at $26.08 47% of stake
    Traded Jun 26 Filed Jun 29
    ↗
  3. James Kihara Principal Accounting Officer
    Sale
    $114K 5,401 shares at $21.18 18% of stake
    Traded May 26 Filed May 27
    ↗
  4. James M Daly Director
    Sale
    $671K 30,000 shares at $22.37 88% of stake
    Traded Nov 10, 2025 Filed Nov 12, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 25 option exercises, 19 sales to cover taxes, and 3 stock grants.

SEC filings

Recent issuer filings from EDGAR, 13 shown.

Filed Form Detail Links
8-K 5.02 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.726B $0.958B $1.07B
Gross profit * $684.8M $875.96M $982.51M
Gross margin * 94.3% 91.5% 91.7%
Net income -$61.29M $226.45M $391M
Net margin * -8.4% 23.6% 36.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.616B $0.938B $1.06B
Total non-current assets * $132.83M $249.44M $502.08M
Total assets $0.749B $1.19B $1.56B
Total current liabilities $254.25M $394.87M $277.11M
Total non-current liabilities * $62.95M $60.09M $59.69M
Total equity $0.432B $0.733B $1.23B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $16.7M $157.72M $109.84M
Cash from investing $32M -$30.54M -$302.56M
Cash from financing $25.13M $6.84M $49.88M
Net change in cash $73.81M $133.93M -$142.82M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.